Vectus Biosystems (VBS) Short Interest
Vectus Biosystems (ASX:VBS) had 0.00% of shares reported as short positions as of 30 July 2026, representing 1,054 shares. Vectus Biosystems operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Vectus Biosystems
Vectus Biosystems is a medical research and development company focused on developing therapies for fibrosis and hypertension. Their lead drug candidate, VB0004, is undergoing Phase I human trials as an anti-fibrotic treatment. The company intends to remain a research and development entity, licensing its current and future technologies.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4VBS intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Vectus Biosystems
Latest VBS news
All news- Vectus Biosystems Ltd (ASX: VBS) Shares Rise as One-Year Gains Reach 372.97% - Kalkine
googlenews
- VBS Engages CHRS as Regulatory Agent for FDA Submissions
asx
- What's Driving Vectus Biosystems' (ASX: VBS) Share Price? - Kalkine
googlenews
- Why Is Vectus Biosystems (ASX:VBS) on Investors' Radar Despite Today's Pullback? - Kalkine
googlenews
- Cleansing Notice
asx
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss VBS
Start a research thread or post the first pulse update